23 results
Thumbnail

D1.90 - Remission of asthma on biological therapy: one center experience

Thumbnail

D1.98 - MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic properties

Thumbnail

D1.102 - Md

Thumbnail

D1.88 - Mepolizumab and intestinal parasitic infection: A case report

Thumbnail

D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)

Thumbnail

D1.92 - Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe

Thumbnail

D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Thumbnail

D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Thumbnail

D1.95 - Dupilumab-induced eosinophilia: a transient effect

Thumbnail

D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)

Thumbnail

D1.99 - Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP

Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy

Thumbnail

D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients

Thumbnail

D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis

Thumbnail

D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment